SCHEMBL3539779

SCHEMBL3539779

Cc1[c]ncc(C(=O)O)c1N1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
POLB P06746 2/20 0.38
DHODH Q02127 2/20 0.37
ALDH1A1 P00352 5/20 0.36
JAK2 O60674 1/20 0.35
IP6K1 Q92551 1/20 0.35
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
CNR2 P34972 1/20 0.33
PDE4B Q07343 1/20 0.33
LMNA P02545 1/20 0.33
CASP1 P29466 1/20 0.33
PTPN1 P18031 1/20 0.33
PKM P14618 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3545222 0.84 OPRK1 (0.40) SMN1; SMN2POLBKDM4EPDE4BMAPT
SCHEMBL3537755 0.79 SMN1; SMN2 (0.41) SMN1; SMN2POLBDHODHALDH1A1JAK2
SCHEMBL3545684 0.78 POLB (0.33) SMN1; SMN2POLBALDH1A1GAAKDM4E
SCHEMBL3546952 0.76 NPSR1 (0.37) SMN1; SMN2POLBALDH1A1GAAKDM4E
SCHEMBL3771669 0.72 MAPT (0.35) SMN1; SMN2POLBALDH1A1GAAKDM4E
SCHEMBL30485938 0.72 HCAR2 (0.49) SMN1; SMN2POLBALDH1A1IP6K1KDM4E
SCHEMBL4787747 0.72 NPC1 (0.45) SMN1; SMN2POLBALDH1A1IP6K1GAA
SCHEMBL27884290 0.70 MYC (0.46) SMN1; SMN2POLBDHODHALDH1A1IP6K1
SCHEMBL15415816 0.70 DHODH (0.41) SMN1; SMN2POLBDHODHALDH1A1JAK2
SCHEMBL15415487 0.70 DHODH (0.41) SMN1; SMN2POLBDHODHALDH1A1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO claimed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 SMN1; SMN2 4452/4885POLB 1231/4885DHODH 80/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 SMN1; SMN2 4458/4885POLB 1483/4885DHODH 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.